SCHEMBL9958801

SCHEMBL9958801

CCOC(=O)CCCCCC(=O)CC(=O)OCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.56
MGAM O43451 1/20 0.56
SI P14410 1/20 0.56
MGAM2 Q2M2H8 1/20 0.56
CYP1A2 P05177 1/20 0.55
ALDH1A1 P00352 3/20 0.50
ALOX15 P16050 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
DGKA P23743 1/20 0.50
CYP3A4 P08684 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KMT2A Q03164 2/20 0.49
EPHX2 P34913 3/20 0.48
PAM P19021 2/20 0.46
USP2 O75604 1/20 0.45
NR1I2 O75469 1/20 0.44
PGR P06401 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28065008 1.00 GAA (0.56) GAAMGAMSIMGAM2CYP1A2
SCHEMBL6138808 0.98 GAA (0.58) GAAMGAMSIMGAM2CYP1A2
SCHEMBL4476235 0.96 GAA (0.61) GAAMGAMSIMGAM2CYP1A2
SCHEMBL6303688 0.96 GAA (0.61) GAAMGAMSIMGAM2CYP1A2
SCHEMBL1223746 0.94 GAA (0.58) GAAMGAMSIMGAM2CYP1A2
SCHEMBL19127030 0.92 TSHR (0.52) GAAMGAMSIMGAM2CYP1A2
SCHEMBL3777425 0.90 HAO1 (0.55) GAAMGAMSIMGAM2DGKA
SCHEMBL6138705 0.90 HAO1 (0.55) GAAMGAMSIMGAM2DGKA
SCHEMBL6138882 0.90 HAO1 (0.55) GAAMGAMSIMGAM2DGKA
SCHEMBL3442509 0.90 HAO1 (0.55) GAAMGAMSIMGAM2DGKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661428-B1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2017-06-07 EP disclosed
US-9469615-B2 Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators MERCK SHARP & DOHME CORP. (US) 2016-10-18 US disclosed
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-14 US disclosed
EP-2661428-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS Merck Sharp & Dohme Corp. (US) 2013-11-13 EP disclosed
WO-2012087861-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303517-A1 QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS HRH2, NPY2R, CNKSR1 GAA 2408/4885MGAM 4631/4885SI 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.